Transcatheter Aortic Valve Replacement in Degenerated Perceval Bioprosthesis: Clinical and Technical Aspects in 32 Cases

Background: Sutureless aortic bioprostheses are increasingly being used to provide shorter cross-clamp time and facilitate minimally invasive aortic valve replacement. As the use of sutureless valves has increased over the past decade, we begin to encounter their degeneration. We describe clinical outcomes and technical aspects in patients with degenerated sutureless Perceval (CorCym, Italy) aortic bioprosthesis treated with valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). Methods: Between March 2011 and March 2023, 1310 patients underwent aortic valve replacement (AVR) with Perceval bioprosthesis implantation. Severe bioprosthesis degeneration treated with VIV-TAVR occurred in 32 patients with a mean of 6.4 +/- 1.9 years (range: 2-10 years) after first implantation. Mean EuroSCORE II was 9.5 +/- 6.4% (range: 1.9-35.1%). Results: Thirty of thirty-two (94%) VIV-TAVR were performed via transfemoral and two (6%) via transapical approach. Vascular complications occurred in two patients (6%), and mean hospital stay was 4.6 +/- 2.4 days. At mean follow-up of 16.7 +/- 15.2 months (range: 1-50 months), survival was 100%, and mean transvalvular pressure gradient was 18.7 +/- 5.3 mmHg. Conclusion: VIV-TAVR is a useful option for degenerated Perceval and appears safe and effective. This procedure is associated with good clinical results and excellent hemodynamic performance in our largest single-center experience.

Automated summary

This study explores the clinical outcomes and technical aspects of using valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) to treat degenerated Perceval aortic bioprostheses. The results show that this treatment option is safe, effective, and associated with good clinical and hemodynamic results.